BOA2019 - Lung
Highlights from the best scientific abstracts in thoracic radiotherapy from ASTRO 2019 will be reviewed and placed in perspective with current literature, practice guidelines and patterns of care. Attendees should leave with a better understanding of how to incorporate these data into daily practice. The 2019 planning committees reviewed potential barriers in patient management and noted that in the treatment of thoracic malignancies, advances are reported almost daily and failure to stay informed can lead to missed opportunities to improve patient care and outcomes. It is increasingly challenging for the clinician to optimally incorporate these advances into daily practice while understanding observed toxicities and adverse interactions, particularly as related to hypofractionation, postoperative radiation and immunotherapy. The management of small cell lung cancer continues to evolve, particularly with respect to PCI and thoracic radiotherapy and new outcome and toxicity data will be reviewed.
The meeting is designed to meet the interests of radiation oncologists and residents.
- Identify evidence for the prophylactic role of radiation in small cell lung cancer.
- Recognize the role of advanced radiation techniques such as hippocampal-sparing prophylactic cranial irradiation and stereotactic ablative radiotherapy in small cell lung cancer.
- Analyze the evidence for hypofractionation in thoracic radiotherapy for non-small cell lung cancer, as well as potential risks or toxicities of its use outside of clinical trials.
- Describe new evidence regarding cardiac dose recommendations for thoracic radiotherapy.
- Evaluate recent evidence or ongoing studies evaluating the incorporation of immunotherapy with thoracic radiotherapy (standard/hypofractionated/SBRT) in the definitive, metastatic or oligometastatic setting.
The following persons served as faculty for this activity:
Inga Grills, MD is employed at Beaumont Health System and has no other disclosures.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.